FDA warns of BD needle sets linked to four deaths

Aug 5, 2026

Becton Dickinson is recalling specific lots of its Intraosseous Vascular Access System Needle Sets manufactured between September 2024 and June 2026 due to a manufacturing defect. The defect causes the obturator to lock into the needle hub, delaying critical care. The issue is associated with 75 complaints, including 45 serious injuries and four patient deaths during cardiac arrest resuscitation. The FDA issued an early alert on August 4, 2026, while Becton Dickinson has instructed customers to destroy affected units.

BD intraosseous needle recall

▪Becton Dickinson identified the root cause of the needle set issue and implemented product and labeling improvements to prevent recurrence.
▪Becton Dickinson issued a nationwide recall of specific lots of its Intraosseous Vascular Access System Needle Sets manufactured between September 2024 and June 2026.

Manufacturing defect obturator locking

▪When the obturator locks into the Becton Dickinson needle hub, clinicians may experience difficulty removing it, requiring a new needle or alternative vascular access and delaying therapy.
▪Certain lots of Becton Dickinson Intraosseous Vascular Access System Needle Sets were manufactured with out-of-tolerance dimensions, causing the obturator to rotate and lock into the needle hub during insertion.

Patient deaths serious injuries

▪Becton Dickinson received 75 total complaints regarding the Intraosseous Vascular Access System Needle Set issue.
▪The four reported deaths associated with Becton Dickinson needle sets occurred during resuscitation efforts for cardiac arrests where clinicians were unable to remove the stylet.
▪As of July 22, 2026, Becton Dickinson reported four patient deaths and 45 serious injuries associated with the Intraosseous Vascular Access System Needle Set defect.

FDA early alert

▪The Food and Drug Administration stated it is reviewing the Becton Dickinson needle set issue and will inform the public as new information becomes available.
▪The Food and Drug Administration issued an early alert on August 4, 2026, warning the public of high-risk issues with Becton Dickinson Intraosseous Vascular Access System Needle Sets.

Customer destruction instructions

▪Becton Dickinson stated that no additional steps are required for patients in whom a potentially affected needle is currently in use and functioning properly.
▪Becton Dickinson instructed distributors to check inventory, destroy affected kits, notify customers, and provide product replacement or credit for destroyed products.
▪On July 30, 2026, Becton Dickinson sent a letter instructing affected customers to immediately discontinue using and destroy all affected needle set lots.

Emergency vascular access devices

▪Critically ill patients requiring urgent vascular access, such as those experiencing out-of-hospital cardiac arrest or severe trauma, face the greatest risk from the Becton Dickinson needle set failure.
▪The Becton Dickinson Intraosseous Vascular Access System is designed to provide vascular access in the proximal tibia, distal tibia, humeral head, or distal femur when intravenous access is difficult or impossible.